Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September

Rhea-AI Summary

Impel Pharmaceuticals (NASDAQ: IMPL) is set to participate in two investor conferences in September 2022. The first event is the H.C. Wainwright 24th Annual Global Investment Conference, where CEO Adrian Adams will engage in a fireside chat on September 13 at 5:00 p.m. ET. The second event is the Guggenheim Nantucket Therapeutics Conference, featuring John Leaman, M.D., on September 29 at 11:00 a.m. ET. Both discussions will be webcast live on the company's investor relations website, with a replay available for 90 days.

SEATTLE, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that the Company will participate in two upcoming investor conferences in September:

• H.C. Wainwright 24th Annual Global Investment Conference: Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat on Tuesday, September 13, 2022 at 5:00 p.m. ET in New York, NY.
  
  
• Guggenheim Nantucket Therapeutics Conference: John Leaman, M.D., Chief Financial and Business Officer, will participate in a fireside chat on Thursday, September 29, 2022 at 11:00 a.m. ET in Nantucket, MA.
  

A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.

About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD^® technology with well-established therapeutics. In addition to Trudhesa^® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit www.ImpelPharma.com

Contact:

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com

Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com

 

FAQ

What is the date and time of Impel Pharmaceuticals' participation in the H.C. Wainwright conference?

Impel Pharmaceuticals will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 5:00 p.m. ET.

Who will represent Impel Pharmaceuticals at the Guggenheim Nantucket Therapeutics Conference?

John Leaman, M.D., the Chief Financial and Business Officer, will represent Impel Pharmaceuticals at the Guggenheim Nantucket Therapeutics Conference on September 29, 2022, at 11:00 a.m. ET.

Where can I watch the live webcast of Impel Pharmaceuticals' conference presentations?

The live webcast of the events will be available on the Investors section of the Impel Pharmaceuticals website.

How long will the replays of the presentations from Impel Pharmaceuticals be available?

Replays of the presentations will be available on the Impel Pharmaceuticals website for 90 days.

What focus does Impel Pharmaceuticals have in terms of its product development?

Impel Pharmaceuticals focuses on developing transformative therapies for diseases with high unmet medical needs, particularly in the central nervous system.